Research Topics
| Barbara K MartinSummaryAffiliation: Johns Hopkins Bloomberg School of Public Health Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Double placebo design in a prevention trial for Alzheimer's diseaseBarbara K Martin
Department of Epidemiology, Center for Clinical Trials, Bloomberg School of Hygiene and Public Health, The Johns Hopkins University, 615 N Wolfe Street, Baltimore, MD 21205, USA
Control Clin Trials 23:93-9. 2002..The authors outline the placebo designs considered in ADAPT, discuss their advantages and disadvantages, and provide their rationale for and the consequences of the selection of the double placebo design...- Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitisBarbara K Martin
Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
Clin Infect Dis 44:1001-8. 2007..In the mid-1990s, the incidence of cytomegalovirus (CMV) resistance to ganciclovir was estimated to be approximately 25% by 1 year after diagnosis of retinitis in patients with acquired immunodeficiency syndrome... - Design of Depression in Alzheimer's Disease Study-2Barbara K Martin
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Am J Geriatr Psychiatry 14:920-30. 2006.... - Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administrationBarbara K Martin
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 40:428-33. 2005..To assess the impact of subcutaneous and intravenous interleukin-2 (IL-2) on health-related quality of life (HRQOL) in adults with HIV-1 receiving highly active antiretroviral therapy (HAART)... - Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: correlation of genotypic methods with viral phenotype and clinical outcomeDouglas A Jabs
Department of Ophthalmology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA
J Infect Dis 193:1728-37. 2006..The cytomegalovirus (CMV) UL97 gene can be sequenced either from blood specimens directly amplified by polymerase chain reaction (PCR) or from culture isolates, to detect resistance to ganciclovir... - Cytomegalovirus (CMV) blood DNA load, CMV retinitis progression, and occurrence of resistant CMV in patients with CMV retinitisDouglas A Jabs
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
J Infect Dis 192:640-9. 2005..CMV load has limited clinical utility, because of its low positive predictive value. Its high negative predictive value for occurrence of resistant CMV suggests that it may have utility as a screening tool to exclude resistance... 
Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?Lea T Drye
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Int J Geriatr Psychiatry 26:573-83. 2011..To determine if the effect of sertraline in the depression in Alzheimer's disease study - 2 (DIADS-2) differed in subgroups of patients defined by baseline depression criteria...- Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitisDouglas A Jabs
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Am J Ophthalmol 135:26-34. 2003..To evaluate whether cytomegalovirus resistant to ganciclovir, detected in either the blood or urine, correlates with adverse ocular outcomes... - Sertraline for the treatment of depression in Alzheimer diseasePaul B Rosenberg
Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Am J Geriatr Psychiatry 18:136-45. 2010..The authors conducted a multicenter, randomized, placebo-controlled trial titled "Depression in Alzheimer's Disease-2" to assess the efficacy and tolerability of sertraline for depression in AD... - Sertraline for the treatment of depression in Alzheimer disease: genetic influencesMatthew E Peters
The Johns Hopkins University, Baltimore, MD 21224, USA
J Geriatr Psychiatry Neurol 24:222-8. 2011..Treatment response by genotype was measured by (1) the modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change, (2) the Cornell scale for Depression in Dementia, and (3) remission of depression... - Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer diseaseCynthia A Munro
Johns Hopkins School of Medicine, Baltimore, MD, USA
Am J Geriatr Psychiatry 20:1036-44. 2012..The authors report cognitive outcomes in patients with depression of AD (dAD) after a 24-week trial of sertraline or placebo... - Evaluation of the United States public health service guidelines for discontinuation of anticytomegalovirus therapy after immune recovery in patients with cytomegalovirus retinitisJanet T Holbrook
Center for Clinical Trials, Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21232, USA
Am J Ophthalmol 152:628-637.e1. 2011.... - The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapyJohn H Kempen
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Ophthalmology 110:987-95. 2003..Newly diagnosed CMV retinitis also is associated with lower general health-related QOL in most domains and with lower health utility... - Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'Paul B Rosenberg
Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Int J Geriatr Psychiatry 20:119-27. 2005..Criteria for the diagnosis of dAD have been proposed previously... - Comparison of cytomegalovirus (CMV) UL97 gene sequences in the blood and vitreous of patients with acquired immunodeficiency syndrome and CMV retinitisHuiling Hu
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Infect Dis 185:861-7. 2002..Although the number of mutations limits definitive interpretation, these data suggest that blood specimens may reflect the events occurring in the eyes of patients with CMV retinitis... - The impact of anemia on energy and physical functioning in individuals with AIDSRichard D Semba
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Arch Intern Med 165:2229-36. 2005..To our knowledge, the relationship between changes in hemoglobin level and energy and physical functioning in the anemic and "normal" ranges of hemoglobin among individuals with AIDS has not been well characterized... - The trialist, meta-analyst, and journal editor: lessons from ADAPTBarbara K Martin
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Am J Med 120:192-3. 2007 - Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factorsMilo A Puhan
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
Clin Infect Dis 51:947-56. 2010..We assessed temporal changes in excess mortality and elucidated risk factors for excess mortality in patients with AIDS diagnosed in the era of highly active antiretroviral therapy (HAART)... - H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidineMichelle C Carlson
Department of Mental Hygiene, and Center on Aging and Health, The Johns Hopkins University School of Public Health, Baltimore, Maryland 21205, USA
Alzheimer Dis Assoc Disord 16:24-30. 2002..To evaluate the efficacy of nizatidine, a histamine H2-blocking drug, in delaying the progression of cognitive impairment in older adults with Alzheimer disease (AD)... - Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitisAdriana Weinberg
University of Colorado Health Sciences Center, Denver, Colorado, USA
J Infect Dis 187:777-84. 2003..016). The incidence of foscarnet resistance after 6, 9, and 12 months of therapy was 13%, 24%, and 37%, respectively... - Comparability of two fundus photograph reading centers in grading cytomegalovirus retinitis progressionLarry D Hubbard
Department of Ophthalmology and Visual Sciences, The University of Wisconsin Medical School, Madison Wisconsin 53711 1068, USA
Am J Ophthalmol 137:426-34. 2004..To compare grading of cytomegalovirus retinitis progression by two different fundus photograph reading centers (FPRCs)... - Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxibBarbara K Martin
Arch Neurol 65:896-905. 2008..CONCLUSIONS: Use of naproxen or celecoxib did not improve cognitive function. There was weak evidence for a detrimental effect of naproxen...
Research Grants
- Depression in Alzheimer's Disease-IICurtis Meinert; Fiscal Year: 2007..The predictive validity of defining depression in AD using a symptom scale or each of these syndromes will be assessed longitudinally against the various study outcomes, and against efficacy of response to antidepressant treatment. ..